RTW Biotech Opportunities Ltd

Declaration of Voting Results & Voting Rights Announcements • Jul 21, 2020

National Storage Mechanism | Additional information

RNS Number : 5444T

RTW Venture Fund Limited

21 July 2020

LEI: 549300Q7EXQQH6KF7Z84

21 July 2020

RTW Venture Fund Limited

Quarterly Update

RTW Venture Fund Limited (the "Company") is pleased to announce that the Fact Sheet for the quarter ended 30 June 2020 is now available on the Company's website in the Document Library Section www.rtwfunds.com/venture-fund.

For Further Information

RTW Investments, LP                                                                              +1 (646) 343 9280

Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

Ocorian (Company Secretary)                                                           +44 (0)1481 742 642

Kevin Smith

J.P. Morgan Cazenove                                                                         +44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

Barclays                                                                                                  +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

Alwyn Clarke

Ryan McCarthy

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DOCFZGZNVGRGGZM